 |
|
Study: Delaying evolution of drug resistance in malaria parasite possible
September 05, 2008GAINESVILLE, Fla. --- There's no magic bullet for wiping out malaria, but a new study offers strong support for a method that effectively delays the evolution of drug resistance in malaria parasites, a University of Florida researcher says.
David Smith, associate director of disease ecology at UF's Emerging Pathogens Institute, said the study will guide scientists and policy makers in extending the longevity of current artemisinin-based malaria drugs combined with partner drugs. Smith is a co-author of a report on the study, scheduled to publish online this week in the Proceedings of the National Academy of Sciences and in print on Sept. 16.
Smith collaborated with lead author Maciej Boni of Resources for the Future and Princeton University, and Ramanan Laxminarayan, also with RFF, to create mathematical models assessing the strategic effectiveness and clinical outcomes of using one, two and three first-line drug therapies to treat malaria within a population over a 20-year period. Their results show that using two or three drugs simultaneously reduced the total clinical cases and number of failed treatments , and slowed the rate at which drug-resistant genes spread within the parasites that cause malaria: Plasmodium falciparum, P. vivax, P. malariae and P. ovale.
"The models indicate that we can slow the evolution of resistance to current artemisinin-based therapies if nations use them in combination with two or more partner drugs," Smith said. "Currently, most nations don't do this. They use one therapy at a time, wait for it to fail, and then switch to a different therapy."
Artemisinin-combined therapies, or ACTs, are currently not widely implemented due to operational challenges and expense, Smith said. But he said the study offers compelling evidence for global leaders to collaborate and overcome these issues.
"This is not to say that implementing multiple first-line therapies solves all of our malaria problems," Boni said. "Anti-malarial drug development needs to continue so that we have novel and highly effective anti-malarials that can be plugged into the recommended strategy of deploying multiple therapies."
In the past century, chloroquine and sulfadoxine-pyrimethamine were widely used to combat malaria, but the parasites eventually evolved resistance leading to the drugs' failure. Artemesinin drugs, derived from the herb Artemisia annua, are relatively new and the malaria parasite does not yet appear to have a resistance to it. They work by triggering chemical reactions which damage the Plasmodium parasite.
"We don't have anything in the pipeline after ACTs, and it's basically just a matter of time until drug resistance evolves and artemisinin also fails," Smith said. "So the question becomes how do we keep ACTs in our arsenal for as long as effectively possible?"
The researchers' models also show that cycling through single drugs accelerated the rate at which malaria parasites evolved drug resistance. Smith said this occurred because cycling a single drug degraded the parasite's average fitness, which made it easier for drug-resistant genes to spread throughout the parasite population.
The cycling models predicted a declining therapeutic value of a single drug within 3.54 years, versus a longer effective therapeutic value of 9.95 years when three drugs were used in equal proportions within a population. The research was funded in part by grants from the Bill and Melinda Gates Foundation, and the National Institutes of Health.
"Using multiple first-line drugs reduces the selection pressure for resistance to a single drug," Smith said. "This is one way to make the ACTs last longer and benefit more people."
Co-author Laxminarayan, a senior research fellow at RFF, said ACTs are the best treatment option for malaria, now as well as in the foreseeable future.
"Novel treatment strategies improve our ability to delay the emergence of drug resistance without the need to deny treatment," Laxminarayan said.
Wil Milhous, associate dean for research at the University of South Florida's College of Public Health, said the research is "clearly a superb breakthrough in mathematical modeling applied to malaria drug deployment." Milhous has worked to develop new drugs for malaria for more than 25 years and is unaffiliated with the study.
"We have done the math in drug development, but only in terms of the cost of goods for drug combinations to include advanced preclinical and clinical testing. These are extremely time-consuming and costly but critical to regulatory approval," Milhous said. "Now we have a highly quantitative reality check that poor implementation strategies doom drugs to failure."
University of Florida
"The models indicate that we can slow the evolution of resistance to current artemisinin-based therapies if nations use them in combination with two or more partner drugs," Smith said. "Currently, most nations don't do this. They use one therapy at a time, wait for it to fail, and then switch to a different therapy."
Artemisinin-combined therapies, or ACTs, are currently not widely implemented due to operational challenges and expense, Smith said. But he said the study offers compelling evidence for global leaders to collaborate and overcome these issues.
"This is not to say that implementing multiple first-line therapies solves all of our malaria problems," Boni said. "Anti-malarial drug development needs to continue so that we have novel and highly effective anti-malarials that can be plugged into the recommended strategy of deploying multiple therapies."
In the past century, chloroquine and sulfadoxine-pyrimethamine were widely used to combat malaria, but the parasites eventually evolved resistance leading to the drugs' failure. Artemesinin drugs, derived from the herb Artemisia annua, are relatively new and the malaria parasite does not yet appear to have a resistance to it. They work by triggering chemical reactions which damage the Plasmodium parasite.
"We don't have anything in the pipeline after ACTs, and it's basically just a matter of time until drug resistance evolves and artemisinin also fails," Smith said. "So the question becomes how do we keep ACTs in our arsenal for as long as effectively possible?"
The researchers' models also show that cycling through single drugs accelerated the rate at which malaria parasites evolved drug resistance. Smith said this occurred because cycling a single drug degraded the parasite's average fitness, which made it easier for drug-resistant genes to spread throughout the parasite population.
The cycling models predicted a declining therapeutic value of a single drug within 3.54 years, versus a longer effective therapeutic value of 9.95 years when three drugs were used in equal proportions within a population. The research was funded in part by grants from the Bill and Melinda Gates Foundation, and the National Institutes of Health.
"Using multiple first-line drugs reduces the selection pressure for resistance to a single drug," Smith said. "This is one way to make the ACTs last longer and benefit more people."
Co-author Laxminarayan, a senior research fellow at RFF, said ACTs are the best treatment option for malaria, now as well as in the foreseeable future.
"Novel treatment strategies improve our ability to delay the emergence of drug resistance without the need to deny treatment," Laxminarayan said.
Wil Milhous, associate dean for research at the University of South Florida's College of Public Health, said the research is "clearly a superb breakthrough in mathematical modeling applied to malaria drug deployment." Milhous has worked to develop new drugs for malaria for more than 25 years and is unaffiliated with the study.
"We have done the math in drug development, but only in terms of the cost of goods for drug combinations to include advanced preclinical and clinical testing. These are extremely time-consuming and costly but critical to regulatory approval," Milhous said. "Now we have a highly quantitative reality check that poor implementation strategies doom drugs to failure."
University of Florida
Malaria Current Events and Malaria News RSSVaccine and drug research aimed at ticks and mosquitoes to prevent disease transmission
Most successful vaccines and drugs rely on protecting humans or animals by blocking certain bacteria from growing in their systems. But, a new theory actually hopes to take stopping infectious diseases such as West Nile virus and Malaria to the next level by disabling insects from transmitting these viruses.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Applying 'supply and demand' business principles to treat infectious diseases worldwide
Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases.
'Airport malaria' -- cause for concern in the US
In a global world, significant factors affect the spread of infectious diseases, including international trade, air travel and globalized food production. "Airport malaria" is a term coined by researchers to explain the more recent spread of malaria to areas such as the United States and Europe, which some scientists credit to warmer climate changes.
Dramatic fall in malaria in the Gambia raises possibility of elimination in parts of Africa
The incidence of malaria has fallen significantly in The Gambia in the last 5 years, according to a study carried out by experts there with support from scientists based in London.
Researchers characterize potential protein targets for malaria vaccine
Researchers from Nijmegen and Leiden have now characterized a large number of parasite proteins that may prove useful in the development of a human malaria vaccine.
Geisinger research: Antimalarial drug prevents diabetes in arthritis patients
The use of an antimalarial medication may prevent the onset of diabetes in patients with rheumatoid arthritis, new Geisinger research shows.
Neighborhood greenness has long term positive impact on kids' health
In the first study to look at the effect of neighborhood greenness on inner city children's weight over time, researchers from the Indiana University School of Medicine, Indiana University-Purdue University Indianapolis and the University of Washington report that higher neighborhood greenness is associated with slower increases in children's body mass over a two year period, regardless of residential density.
Childhood environmental health
Children are exposed to a wide range of environmental threats that can affect their health and development early in life, throughout their youth and into adulthood.
Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa
More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 because a feasible and timely antiretroviral (ARV) treatment program was not implemented, assert researchers from the Harvard School of Public Health (HSPH) in a study published online by the Journal of Acquired Immune Deficiency Syndromes (JAIDS) (http://www.jaids.com/).
More Malaria Current Events and Malaria News Articles
 | The Making of a Tropical Disease: A Short History of Malaria (Johns Hopkins Biographies of Disease) by Randall M. Packard Malaria sickens hundreds of millions of people -- and kills one to three million -- each year. Despite massive efforts to eradicate the disease, it remains a major public health problem in poorer tropical regions. But malaria has not always been concentrated in tropical areas. How did other regions control malaria and why does the disease still flourish in some parts of the globe?From Russia to... |
 | Malaria Dreams: An African Adventure by Stuart Stevens Malaria Dreams is a tale of high adventure across Africa, recounted with the wit and humor that delighted readers of Night Train to Turkistan, Stuart Stevens' highly praised first book. "A rollicking, off-beat African odyssey".--Publishers... |
 | The Malaria Capers : More Tales of Parasites and People, Research and Reality by Robert S. Desowitz Like such eminent science writers as Stephen Jay Gould and Lewis Thomas, Mr. Desowitz manages to make the basic principles of his subject immediately comprehensible to the general reader. He has also succeeded in giving us a profound appreciation of the ways in which scientific and medical knowledge advances, through hypothesis, error and experiment, through serendipity, dedication, and... |
 | The Conquest of Malaria: Italy, 1900-1962 by Frank Snowden At the outset of the twentieth century, malaria was Italy’s major public health problem. It was the cause of low productivity, poverty, and economic backwardness, while it also stunted literacy, limited political participation, and undermined the army. In this book Frank Snowden recounts how Italy became the world center for the development of malariology as a medical discipline and launched... |
 | Molecular Approaches to Malaria "Molecular Approaches to Malaria" provides an overview of the rapid and significant developments that have occurred in malaria research, including the 2002 genome sequencing of Plasmodium falciparum and its mosquito vector, Anopheles gambiae. An important resource for molecular biologists, biochemists, cell biologists, chemists, pathologists, parasitologists, entomologists, and immunologists,... |
| Malaria in the interior valley of North America - A Selection From: 'A Systematic Treatise, Historical, Etiological and Practical on the Principal Diseases...' (1964 Facsimile of 1850 Edition) by Daniel Drake | |
 | Humanity's Burden: A Global History of Malaria (Studies in Environment and History) by James L.A. Webb Jr. Humanity's Burden provides a panoramic overview of the history of malaria. It traces the long arc of malaria out of tropical Africa into Eurasia, its transfer to the Americas during the early years of the Columbian exchange, and its retraction from the middle latitudes into the tropics since the late nineteenth century. Adopting a broadly comparative approach to historical patterns and processes,... |
 | The Miraculous Fever-Tree: Malaria and the Quest for a Cure That Changed the World by Fiammetta Rocco "Cinchona revolutionized the art of medicine as profoundly as gunpowder had the art of war." -- Bernardino Ramazzini, Physician to the Duke of Modena, Opera omnia, medica, et physica, 1716 In the summer of 1623, ten cardinals and hundreds of their attendants died in Rome while electing a new pope. The Roman marsh fever that felled them was the scourge of the Mediterranean, northern Europe... |
 | Malaria - a Handbook for Health Professionals by Malaria Consortium |
 | Malaria: Poverty, Race, and Public Health in the United States by Margaret Humphreys In Malaria: Poverty, Race, and Public Health in the United States, Margaret Humphreys presents the first book-length account of the parasitic, insect-borne disease that has infected millions and influenced settlement patterns, economic development, and the quality of life at every level of American society, especially in the south.Humphreys approaches malaria from three perspectives: the... |
| © 2008 BrightSurf.com |